RESEARCH PAPER
Mild adverse events after administration of iodinated contrast agent in computed tomography examination
 
More details
Hide details
1
Zakład Diagnostyki Obrazowej, Mazowiecki Szpital Specjalistyczny w Ostrołęce
2
Zakład Radiologii, Uniwersytet Medyczny w Białymstoku
3
Zakład Statystyki i Informatyki Medycznej, Uniwersytet Medyczny w Białymstoku
 
Med Og Nauk Zdr. 2015;21(1):7–12
 
KEYWORDS
ABSTRACT
Introduction:
Contrast media in computed tomography facilitate differentiation between tissues, which is useful in verifying initial clinical diagnosis. One of the most commonly used formulations is iodinated monomer Ultravist (Iopromid) soluble in water. The specificity of contrast agents is the possibility of induction of adverse reactions of various types. Mild reactions are rarely reported in literature. The objective of the study was to analyze the types of mild complications after intravenous administration of iodinated contrast agent Ultravist 300 and 370 in computed tomography examinations.

Material and Methods:
The study group comprised 160 patients who during CT scans were administered intravenously Ultravist. The study was conducted by the method of a diagnostic survey, using a survey technique, and the research instrument was a questionnaire designed by the author. The data collected were entered and analyzed using Statistica 10.0 StatSoft and PASW Statistic 17.0 Predictive Solutions; Chi-square test was used to compare differences between proportions; the level of statistical significance was set at 5% (p < 0.05).

Results:
The most common reactions after intravenous administration of contrast medium were the feeling of warmth, feeling of urination and a ‘strange taste in the mouth’. Patients who received Ultravist 300 reported the ‘sensation of warmth throughout the body’ more frequently than those who received Ultravist 370 (p = 0.001). No relationship was confirmed between the amount of synthesized MS and speed of administration, and adverse reactions at the injection site.

Conclusions:
Symptoms of mild adverse events pass spontaneously and do not require pharmacotherapy. These symptoms; however, are important from the point of view of the security and co-operation with the patient while performing the examination, and care of the patient after its completion

 
REFERENCES (23)
1.
Goldman LW. Principles of CT and CT technology. J Nucl Med Technol. 2007; 35(3): 115–128.
 
2.
Goldman LW. Principles of CT: multislide CT. J Nucl Med Technol. 2008; 36(2): 57–68.
 
3.
Prokop M, van der Molen AJ. Przygotowanie pacjenta i podawanie środków cieniujących. W: Gołębiowski M (red.). Spiralna i wielorzędowa tomografia komputerowa człowieka. Wyd. 1. Warszawa: Wydawnictwo Medipage; 2007: 86 – 109.
 
4.
Dawson P. Adverse reactions to intravascular contrast agents. BMJ. 2006; 30(333): 663–664.
 
5.
Kucharczyk A, Jahnz-Różyk K. Nadwrażliwość na środki kontrastujące – jak zmniejszyć ryzyko wystąpienia działań niepożądanych? Internat Rev Allergol Clin Immunol. 2013; 19(2): 127–135.
 
6.
ACR Manual on Contrast Media, Wersja 9.0, American College of Radiology Committee on Drugs and Contrast Media, 2013. http:// www.acr.org/~/media/ACR/Docume... Contrast%20Manual/2013_Contrast_Media.pdf (dostęp: 2013.09.01).
 
7.
Baerlocher MO, Asch M, Myers A. Allergic-type reactions to radio¬graphic contrast media. CMAJ. 2010; 182(12): 1328.
 
8.
Furmanek M. Wyciąg z wytycznych dotyczących stosowania jodowych środków kontrastowych. Wytyczne ESUR, wersja 8.0 (2012). Wyd.1. Warszawa: BAYER, s.7–8.
 
9.
Namasivayam S, Kalra MK, Torres WE, Small WC. Adverse reactions to intravenous iodinated contrast media: a primer for radiologists. Emerg Radiol. 2006; 12(5): 210–215.
 
10.
Ustawa z dnia 6 listopada 2008 r. o prawach pacjenta i Rzeczniku Praw Pacjenta (Dz. U. z 2009 r. Nr 52, poz. 417 z późń. zm.).
 
11.
Podciechowski L, Królikowska A, Hładuńska J, Wilczyński J. Prawo pacjenta do informacji – aspekty prawne, medyczne i psychologiczne. Prz Menopauzalny. 2009; 6: 308–314.
 
12.
Żaba C, Świderski P, Żaba Z, Klimberg A, Przybylski Z. Leczenie na podstawie zgody pacjenta – kontrowersje, wątpliwości, niejasności. Arch Med Sąd Krym. 2007; LVII: 122–127.
 
13.
Mathers SA, Chesson RA, Proctor JM, McKenzie GA, Robertson E. The use of patient-centered outcome measures in radiology: a systematic review. Acad Radiol. 2006; 13: 1394–1404.
 
14.
McCullough PA, Capasso P. Patient discomfort associated with the use of intra-arterial iodinated contrast media: a meta-analysis of com-parative randomized controlled trials. http://www.biomedcentral.com/1... (dostęp: 2013.08.31).
 
15.
Galimany-Masclans J, Garrido-Aguilar E, Pernas-Canadell JC, Díaz-Rodríguez S. Adverse reactions to iodinated contrast media. Enferm Clin. 2010; 20(5): 297–300.
 
16.
Mitchell AM, Jones AE, Tumlin JA, Kline JA. Immediate complications of intravenous contrast for computed tomography imaging in the outpatient setting are rare. Acad Emerg Med. 2011; 18(9): 1005 – 1009.
 
17.
Singh J, Daftary A. Iodinated contrast media and their adverse reactions. J Nucl Med Technol. 2008; 36(2): 69–74.
 
18.
Ho J, Kingston RJ, Young N, Katelaris CH, Sindhusake D. Immediate hypersensitivity reactions to IV non-ionic iodinated contrast in com-puted tomography. Asia Pac Allergy. 2012; 2(4): 242–247.
 
19.
Kopp AF, Mortele KJ, Cho YD, Palkowitsch P, Bettmann MA, Claussen CD. Prevalence of acute reactions to Iopromide: postmarketing surveillance study of 74.717 patients. Acta Radiol. 2008; 49: 902–911.
 
20.
Palkowitsch P, Lengsfeld P, Stauch K, Heinsohn C, Kwon ST, Zhang S. i wsp. Safety and diagnostic image quality of Iopromide: results of a large non-interventional observational study of European and Asian patients (IMAGE). Acta Radiol. 2012; 53: 179–186.
 
21.
Gharekhanloo F, Torabian S. Comparison of allergic adverse effects and contrast enhancement between Iodixanol and Iopromide. Iran J Radiol. 2012; 9(2): 63–6.
 
22.
Baerlocher MO, Asch M, Myers A. The use of contrast media. CMAJ. 2010; 182(7): 697.
 
23.
Dyrla P, Wojtuń S, Gil J. Zasady przygotowania i warunki wykonania badań obrazowych przewodu pokarmowego. Pol Merk Lek. 2007; XXII (131): 482–488.
 
eISSN:2084-4905
ISSN:2083-4543